# US 2003/0211511 A1 · Nucleic acids and proteins with thioredoxin reductase activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211511 A1
- Document ID: US20030211511A1
- Status: Published application
- Kind: A1
- Application number: 10/290,072
- Filed: 2002-11-06
- Published: 2003-11-13
- Earliest claimed: 2001-05-04
- Inventors: Steven P. Briggs; Bipin K. Dalmia; Greg del Val; John R. Desjarlais; Peter Heifetz; Peter Luginbuhl; Umesh Muchhal
- Web page: https://patentgrep.com/patent/US20030211511A1

## CPC

- C12N 9/0036: {acting on NADH or NADPH (1.6)}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 15/8242: {with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits}
- C12N 15/8257: {for the production of primary gene products, e.g. pharmaceutical products, interferon}
- C12Y 108/01009: Thioredoxin-disulfide reductase (1.8.1.9), i.e. thioredoxin-reductase
- C07K 2319/00: Fusion polypeptide
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to the use of a variety of methods for generating functional thioredoxin reductase variants in which at least one physical, chemical or biological property of the variant is altered in a specific and desired manner when compared to the wild-type protein.

## Claims

### Claim 1

A fusion polypetide comprising:
a) a thioredoxin protein; and,
b) a thioredoxin reductase protein.

### Claim 2 (depends on 1)

A fusion polypeptide according to claim 1, wherein the C-terminal end of said thioredoxin protein is fused to the N-terminal end of said thioredoxin reductase protein.

### Claim 3 (depends on 1)

A fusion polypeptide according to claim 1 wherein said thioredoxin protein and said thioredoxin reductase proteins are selected from the group consisting of E. coli, Bacillus subtillis, Mycobacterium leprae, Sarccharomyces, Neurospora crassa, Arabidopsis, and human.

### Claim 4 (depends on 1)

A fusion polypeptide according to claim 1, wherein said thioredoxin reductase is a wild-type protein.

### Claim 5 (depends on 1)

A fusion polypeptide according to claim 1, wherein said thioredoxin reductase protein is a variant thioredoxin reductase protein and wherein said cofactor specificity of said variant thioredoxin reductase protein is NADPH or NADH.

### Claim 6 (depends on 5)

A fusion polypeptide according to claim 5, wherein said cofactor specificity of said variant thioredoxin reductase is switched to NADH.

### Claim 7 (depends on 5)

A fusion polypeptide according to claim 5, wherein said cofactor specificity of said variant thioredoxin reductase is altered such that said variant preferentially binds NADPH compared to NADH.

### Claim 8 (depends on 5)

A fusion polypeptide according to claim 5, wherein said cofactor specificity of said variant thioredoxin reductase is altered such that said variant preferentially binds NADH compared to NADPH.

### Claim 9 (depends on 5)

A fusion polypeptide according to claim 5, wherein said cofactor specificity of said variant thioredoxin reductase is altered such that said variant exhibits improved catalytic efficiency for NADPH as compared to a wild-type thioredoxin reductase protein.

### Claim 10 (depends on 1)

The fusion polypeptide according to claim 1, wherein said thioredoxin protein is fused to said thioredoxin reductase protein through a linker.

### Claim 11 (depends on 10)

The fusion polypeptide molecule according to claim 10, wherein said linker comprises a polypeptide sequence having between about 5 and about 50 amino acids.

### Claim 12 (depends on 10)

The fusion polypeptide molecule according to claim 10, wherein said linker comprises a polypeptide sequence having between about 10 and about 40 amino acids.

### Claim 13 (depends on 10)

The fusion polypeptide molecule according to claim 10, wherein said linker comprises a polypeptide sequence having between about 15 and about 25 amino acids.

### Claim 14 (depends on 1)

The fusion polypeptide molecule according to claim 1, further comprising a peptide tag operably linked in-frame with said thioredoxin or thioredoxin reductase.

### Claim 15 (depends on 14)

The fusion polypeptide molecule according to claim 14, wherein said peptide tag is linked via a linker to said thioredoxin or thioredoxin reductase.

### Claim 16 (depends on 1)

The fusion polypeptide molecule according to claim 1 further comprising a signal peptide operaly linked in-frame with said thioredoxin or thioredoxin reductase.

### Claim 17 (depends on 16)

The fusion polypeptide molecule according to claim 16 wherein said signal peptide is a secretion signal.

### Claim 18 (depends on 16)

The fusion polypeptide molecule according to claim 16 wherein said signal peptide is an organelle targeting peptide.

### Claim 19 (depends on 16)

The fusion polypeptide molecule according to claim 16 wherein said signal peptide is operably linked to said thioredoxin or thioredoxin reductase via a linker.

### Claim 20 (depends on 16)

The fusion polypeptide molecule according to claim 16, wherein said signal peptide is an oleosin peptide.

### Claim 21 (depends on 1)

The fusion polypetide according to claim 1 wherein said fusion polypeptide encodes a eucaryotic thioredoxin protein fused to a eukaryotic thioredoxin reductase.

### Claim 22 (depends on 1)

The fusion polypetide according to claim 1 wherein said fusion polypeptide encodes a plant thioredoxin protein fused to a plant variant thioredoxin reductase.

### Claim 23 (depends on 22)

The fusion polypetide according to claim 22 wherein said plant is selected from the group consisting of a moncot, a dicot, and algae.

### Claim 24 (depends on 23)

The fuison polypeptide according to claim 23 wherein said moncot is selected from the group consisting of rice, corn, wheat, and barley.

### Claim 25 (depends on 23)

The fusion polypeptide according to claim 23, wherein said dicot is selected from the group consisting of soybean and Arabidopsis.

### Claim 26 (depends on 22)

The fusion polypeptide according to claim 22, wherein said plant thioredoxin reductase protein encodes a variant protein selected from the group consisiting of a variant thioredoxin reductase RYN-A protein, a variant thioredoxin reductase WFQ protein, a WLS protein, and a variant thioredoxin reductase WRT protein.

### Claim 27 (depends on 21)

The fusion polypeptide according to claim 21, wherein said fusion protein encodes a human thioredoxin fused to a plant variant thioredoxin reductase.

### Claim 28 (depends on 27)

The fusion polypeptide according to claim 27, wherein said plant variant thioredoxin reductase is selected from the group consisting of a dicot, a monocot, and algae.

### Claim 29 (depends on 28)

The fuison polypeptide according to claim 28 wherein said moncot is selected from the group consisting of rice, corn, wheat, and barley.

### Claim 30 (depends on 28)

The fusion polypeptide according to claim 28 wherein said dicot is selected from the group consisting of soybean and Arabidopsis.

### Claim 31 (depends on 28)

The fusion polypeptide according to claim 28, wherein said fusion polypeptide is encodes a human thioredoxin fused to an Arabidopsis variant thioredoxin reductase.

### Claim 32 (depends on 28)

The fusion polypeptide according to claim 28, wherein said plant thioredoxin reductase protein encodes a variant protein selected from the group consisiting of a variant thioredoxin reductase RYN-A protein, a variant thioredoxin reductase WFQ protein, a WLS protein, and a variant thioredoxin reductase WRT protein.

### Claim 33 (depends on 21)

The fusion polypeptide according to claim 21, wherein said fusion polypeptide is encodes a human thioredoxin fused to an human variant thioredoxin reductase.

### Claim 34 (depends on 33)

The fusion polypeptide according to claim 33, wherein said human thioredoxin reductase protein encodes a variant protein selected from the group consisiting of a variant thioredoxin reductase RYN-A protein, a variant thioredoxin reductase WFQ protein, a WLS protein, and a variant thioredoxin reductase WRT protein.

### Claim 35 (depends on 21)

The fusion polypeptide according to claim 21, that is selected from the group consisting of an Arabidopsis thioredoxin protein fused to the Arabidopsis variant thioredoxin reductase RYN-A protein, an Arabidopsis thioredoxin protein fused to the Arabidopsis variant thioredoxin reductase WFQ protein, an Arabidopsis thioredoxin protein fused to the Arabidopsis variant thioredoxin reductase WLS protein, an Arabidopsis thioredoxin protein fused to the Arabidopsis variant thioredoxin reductase WRT protein, a human thioredoxin fused to the Arabidopsis variant thioredoxin reductase RYN-A protein, a human thioredoxin fused to the Arabidopsis variant thioredoxin reductase WFQ protein, a human thioredoxin fused to the Arabidopsis variant thioredoxin reductase WLS protein, a human thioredoxin fused to the Arabidopsis variant thioredoxin reductase WRT protein, a human thioredoxin fused to the human variant thioredoxin reductase RYN-A protein, a human thioredoxin fused to the human variant thioredoxin reductase WFQ protein, a human thioredoxin fused to the human variant thioredoxin reductase WLS protein, and a human thioredoxin fused to the human variant thioredoxin reductase WRT protein.

### Claim 36 (depends on 1)

The fusion polypetide of claim 1 produced in a bacterial, yeast or plant host cell.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method for producing a plant with a fusion polypetide comprising:
(a) introducing an expression cassette comprising a promoter functional in a plant cell operably linked to a DNA molecule encoding a fusion polypeptide according to claims 1-16 comprising an amino terminal plastid transit peptide, into the cells of a plant so as to yield transformed plant cells; and
(b) regenerating said transformed plant cells to provide a differentiated transformed plant expressing said fusion polypeptide; and,
(c) isolating said fusion polypeptide.

### Claim 38 (depends on 37)

The isolated fusion polypeptide according to claim 37 further comprising a pharmaceuticdally acceptable carrier.

### Claim 39 (depends on 1)

A method for making oil bodies comprising a fusion polypeptide comprising:
a) producing in a cell a fusion polypeptide according to claim 1;
b) associating said fusion polypeptide with oil bodies through an oil body targeting protein capable of associating with said fusion polypeptide and said oil bodies; and,
c) obtaining said oil bodies associated with said fusion polypeptide.

### Claim 40 (depends on 39)

A method according to claim 39 further comprising:
a) washing the oil bodies to obtain a washed oil body preparation comprising said fusion polypeptide; and,
b) formulating said washed oil bodies into an emulsion.

### Claim 41 (depends on 39)

A method according to claim 39 wherein said oil bodies are used in the preparation of non-allergenic foods.

### Claim 42 (depends on 39)

A method according to claim 39 wherein said oil bodies are used in the preparation of animal feeds to improve the digestibility of said feeds.
